Zomelis Met 50mg/850mg Tablet is a fixed-dose combination medication containing Metformin hydrochloride 850mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, which inhibit glucagon release and increase insulin secretion in a glucose-dependent manner. The synergistic effect of these two agents provides effective glycemic control by targeting multiple pathophysiological defects in type 2 diabetes. Zomelis Met is typically prescribed as an adjunct to diet and exercise when monotherapy with metformin or other oral antidiabetic agents does not achieve adequate glycemic control. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to any component of the formulation. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is generally low but may increase when combined with other antidiabetic agents. Regular monitoring of renal function and glycemic parameters is recommended during therapy to optimize efficacy and safety.